Biotech stocks saw notable upward momentum in Thursday's after-hours trading session, with several names posting strong percentage gains despite the absence of fresh company-specific developments.
Coherus Oncology, Inc. (CHRS) climbed 9.09% to close at $1.73, adding $0.14 in extended trading.
Sensei Biotherapeutics, Inc. (SNSE) surged 10.06% after hours, finishing at $12.47 with a gain of $1.14.
Cue Biopharma, Inc. (CUE) advanced 9.37% to $0.40, rising $0.034 in after-hours action.
Alpha Tau Medical Ltd. (DRTS) added 3.35% to $7.41, up $0.24. While there was no news Thursday, the company was recently in focus after Taiho Oncology announced on January 20 that Peter Melnyk had joined as President and Chief Operating Officer.
Cingulate Inc. (CING) edged higher by 1.49%, closing at $5.45 after hours with a gain of $0.08.
uniQure N.V. (QURE) posted a strong 9.96% jump to $24.95, adding $2.26 in extended trading.
IO Biotech, Inc. (IOBT) gained 4.19% to $0.50, up $0.020 after hours. While Thursday brought no fresh news, the company recently announced on January 21 that it is exploring a range of strategic alternatives, including potential mergers, asset sales, or even liquidation, alongside cost-cutting measures such as workforce reductions.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.